Arbutus Biopharma’s (ABUS) “Buy” Rating Reaffirmed at HC Wainwright

Arbutus Biopharma (NASDAQ:ABUS)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $5.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 33.33% from the stock’s current price.

Several other research firms have also recently weighed in on ABUS. Jefferies Financial Group lifted their price objective on Arbutus Biopharma from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, September 5th. JMP Securities lifted their price target on shares of Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a research note on Wednesday. Chardan Capital upped their price target on shares of Arbutus Biopharma from $4.00 to $4.50 and gave the company a “buy” rating in a report on Wednesday. Finally, StockNews.com upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 10th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Arbutus Biopharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.38.

Arbutus Biopharma Trading Up 0.5 %

ABUS stock opened at $3.75 on Thursday. Arbutus Biopharma has a 1-year low of $1.70 and a 1-year high of $4.72. The firm has a market cap of $707.93 million, a PE ratio of -8.72 and a beta of 1.92. The business’s 50-day moving average price is $4.03 and its two-hundred day moving average price is $3.58.

Institutional Investors Weigh In On Arbutus Biopharma

Several institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its stake in Arbutus Biopharma by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 36,309 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 14,138 shares during the last quarter. Creative Planning grew its holdings in shares of Arbutus Biopharma by 13.8% in the 3rd quarter. Creative Planning now owns 49,500 shares of the biopharmaceutical company’s stock valued at $191,000 after acquiring an additional 5,989 shares in the last quarter. Helen Stephens Group LLC bought a new position in shares of Arbutus Biopharma in the 3rd quarter valued at about $50,000. SG Americas Securities LLC acquired a new stake in shares of Arbutus Biopharma in the third quarter valued at about $204,000. Finally, Susquehanna Fundamental Investments LLC raised its holdings in Arbutus Biopharma by 102.2% during the second quarter. Susquehanna Fundamental Investments LLC now owns 208,152 shares of the biopharmaceutical company’s stock worth $643,000 after acquiring an additional 105,228 shares in the last quarter. Institutional investors own 43.79% of the company’s stock.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.